1. Home
  2. SRRK vs AHR Comparison

SRRK vs AHR Comparison

Compare SRRK & AHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • AHR
  • Stock Information
  • Founded
  • SRRK 2012
  • AHR 2013
  • Country
  • SRRK United States
  • AHR United States
  • Employees
  • SRRK N/A
  • AHR N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • AHR
  • Sector
  • SRRK Health Care
  • AHR
  • Exchange
  • SRRK Nasdaq
  • AHR NYSE
  • Market Cap
  • SRRK 4.2B
  • AHR 4.5B
  • IPO Year
  • SRRK 2018
  • AHR 2024
  • Fundamental
  • Price
  • SRRK $43.07
  • AHR $28.25
  • Analyst Decision
  • SRRK Strong Buy
  • AHR Buy
  • Analyst Count
  • SRRK 7
  • AHR 8
  • Target Price
  • SRRK $40.43
  • AHR $25.25
  • AVG Volume (30 Days)
  • SRRK 1.2M
  • AHR 2.2M
  • Earning Date
  • SRRK 11-12-2024
  • AHR 02-12-2025
  • Dividend Yield
  • SRRK N/A
  • AHR 3.52%
  • EPS Growth
  • SRRK N/A
  • AHR N/A
  • EPS
  • SRRK N/A
  • AHR N/A
  • Revenue
  • SRRK N/A
  • AHR $2,005,322,000.00
  • Revenue This Year
  • SRRK N/A
  • AHR N/A
  • Revenue Next Year
  • SRRK N/A
  • AHR $6.99
  • P/E Ratio
  • SRRK N/A
  • AHR N/A
  • Revenue Growth
  • SRRK N/A
  • AHR 9.88
  • 52 Week Low
  • SRRK $6.76
  • AHR $12.63
  • 52 Week High
  • SRRK $46.19
  • AHR $29.99
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 69.26
  • AHR 58.28
  • Support Level
  • SRRK $40.95
  • AHR $27.85
  • Resistance Level
  • SRRK $44.22
  • AHR $28.91
  • Average True Range (ATR)
  • SRRK 2.57
  • AHR 0.72
  • MACD
  • SRRK -0.12
  • AHR -0.14
  • Stochastic Oscillator
  • SRRK 73.14
  • AHR 54.39

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About AHR AMERICAN HEALTHCARE REIT INC

American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing primarily on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. They have four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of revenue through Integrated Senior Health Campuses segment.

Share on Social Networks: